WO2012161562A1 - A process for producing nano-capsules and nano-beadlets containing phytonutrients derived from palm oil - Google Patents
A process for producing nano-capsules and nano-beadlets containing phytonutrients derived from palm oil Download PDFInfo
- Publication number
- WO2012161562A1 WO2012161562A1 PCT/MY2012/000106 MY2012000106W WO2012161562A1 WO 2012161562 A1 WO2012161562 A1 WO 2012161562A1 MY 2012000106 W MY2012000106 W MY 2012000106W WO 2012161562 A1 WO2012161562 A1 WO 2012161562A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nano
- phytonutrients
- palm oil
- beadlets
- derived
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 239000002088 nanocapsule Substances 0.000 title claims abstract description 47
- 235000019482 Palm oil Nutrition 0.000 title claims abstract description 34
- 239000002540 palm oil Substances 0.000 title claims abstract description 34
- 239000011731 tocotrienol Substances 0.000 claims abstract description 30
- 229930003802 tocotrienol Natural products 0.000 claims abstract description 28
- 235000019148 tocotrienols Nutrition 0.000 claims abstract description 28
- 229940068778 tocotrienols Drugs 0.000 claims abstract description 25
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 claims abstract description 24
- 239000011257 shell material Substances 0.000 claims abstract description 23
- 150000001746 carotenes Chemical class 0.000 claims abstract description 14
- 235000005473 carotenes Nutrition 0.000 claims abstract description 14
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 6
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 24
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 claims description 22
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- 235000019150 γ-tocotrienol Nutrition 0.000 claims description 16
- 239000000839 emulsion Substances 0.000 claims description 15
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 claims description 15
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims description 15
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 claims description 15
- 239000011722 γ-tocotrienol Substances 0.000 claims description 15
- 235000010489 acacia gum Nutrition 0.000 claims description 14
- 239000000654 additive Substances 0.000 claims description 12
- 230000000996 additive effect Effects 0.000 claims description 12
- 239000005515 coenzyme Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 9
- 239000012454 non-polar solvent Substances 0.000 claims description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 8
- DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical class OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 claims description 7
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 claims description 7
- 235000019144 δ-tocotrienol Nutrition 0.000 claims description 7
- 239000011729 δ-tocotrienol Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 239000007764 o/w emulsion Substances 0.000 claims description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 5
- 229920000084 Gum arabic Polymers 0.000 claims description 5
- 239000000205 acacia gum Substances 0.000 claims description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 5
- 239000011648 beta-carotene Substances 0.000 claims description 5
- 235000013734 beta-carotene Nutrition 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- 239000001110 calcium chloride Substances 0.000 claims description 5
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 5
- 239000012266 salt solution Substances 0.000 claims description 5
- 238000000527 sonication Methods 0.000 claims description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 5
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 4
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 4
- 239000001751 lycopene Substances 0.000 claims description 4
- 235000012661 lycopene Nutrition 0.000 claims description 4
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 4
- 229960004999 lycopene Drugs 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 abstract description 27
- 238000001727 in vivo Methods 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000000265 homogenisation Methods 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229940064063 alpha tocotrienol Drugs 0.000 description 6
- 239000008393 encapsulating agent Substances 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 235000019145 α-tocotrienol Nutrition 0.000 description 6
- 239000011730 α-tocotrienol Substances 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- JROGBPMEKVAPEH-GXGBFOEMSA-N emetine dihydrochloride Chemical compound Cl.Cl.N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC JROGBPMEKVAPEH-GXGBFOEMSA-N 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 229940068977 polysorbate 20 Drugs 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000001069 triethyl citrate Substances 0.000 description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 4
- 235000013769 triethyl citrate Nutrition 0.000 description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000010413 sodium alginate Nutrition 0.000 description 3
- 239000000661 sodium alginate Substances 0.000 description 3
- 229940005550 sodium alginate Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 150000003786 γ-tocotrienols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
Definitions
- the present invention relates to a process for producing nano-capsules and nano- beadlets containing phytonutrients derived from palm oil.
- Palm phytonutrients such as tocotrienols, carotenes and coenzyme Q are highly sensitive towards lights, temperature, pH and air. In room temperature, these phytonutrients get oxidized by air and thus, their half time is normally very short. In addition, these phytonutrients are also destroyed at extreme acidic conditions, resulting in a reduced bioavailability in vivo. In order to make up for the reduced bioavailability, larger dosage of these phytonutrients needs to be consumed thus, incurring extra cost. Therefore there is a need for encapsulation of these phytonutrients which will ensure stability, hence longer shelf life and bioavailability of the phytonutrients to reap its full benefits.
- the present invention relates to a process for producing nano-capsules containing phytonutrients derived from palm oil.
- The, process includes the steps of:
- step (ii) adding of at least one shell material and at least one additive into the solution obtained from step (i) to form a mixture;
- step (iii) obtaining stable oil in water emulsion by introducing the mixture obtained from step (ii) to a buffer solution;
- step (iv) homogenizing the mixture obtained from step (iv) under pressure of more than 50 bar and/or by using ultrasound;
- the phytonutrients derived from palm oil is such as tocotrienols, carotenes, coenzyme Q, ⁇ -tocotrienol, a-tocotrienol, ⁇ - tocotrienol, lycopene and ⁇ -carotene.
- the present invention also relates to a process for producing nano-beadlets containing phytonutrients derived from palm oil.
- the process includes the steps of:
- step (ii) adding of at least one shell material and at least one additive into the solution obtained from step (i) to form a mixture;
- step (iii) homogenizing the mixture obtained from step (ii) under pressure of more than 50 bar or by way of sonication;
- step (iii) precipitating the phytonutrients from the mixture obtained from step (iii) to form insoluble nano-beadlets;
- the phytonutrients is precipitated by adding the mixture obtained from step (iii) into a salt solution by using an atomizer.
- the salt solution is methanolic solution of calcium chloride.
- the process for producing nano-beadlets containing phytonutrients derived from palm oil further includes the steps of;
- step (i) adding at least one additive into the mixture obtained in step (i);
- the phytonutrients derived from palm oil is such as tocols, coenzyme Qio, tocotrienol, a- tocotrienol, ⁇ -tocotrienol, ⁇ -tocotrienol and carotenes.
- the phytonutrients within the nano-beadlets are slowly released over period of 4 - 6 hours.
- the present invention also relates to a process for producing nano-capsules containing phytonutrients derived from palm oil, the process includes the steps of:
- step (i) mixing phytonutrients with a mixture of gum and coating material in water; ii) homogenizing the mixture obtained from step (i) under pressure of more than 50 bar or by way of sonication;
- step (iv) coating of insoluble solids obtained from step (iii) with shell material; and v) drying of nano-capsules obtained from step (iv).
- the phytonutrients derived from palm oil is such as tocotrienol, carotenes, a-tocotrienol, and ⁇ - tocotrienol, coenzyme Qio.
- the gum is such as arabic gum and acacia gum.
- the coating material is sugar such as lactose.
- the non-polar solvent used for the processes mentioned above is hexane, heptane, chloroform or any combination thereof.
- the shell material used for the processes mentioned above is polymer, sugar, gum or any combination thereof.
- the at least one additive for the processes mentioned above is polymeric.
- the nano-capsules or nano- beadlets obtained from the above mentioned process having size of 20nm - 500nm.
- the present invention relates to a process for producing nano-capsules and nano- beadlets containing phytonutrients derived from palm oil.
- the phytonutrients are such as tocols, tocotrienols, a-tocotrienols, ⁇ -tocotrienols, ⁇ -tocotrienol, coenzyme Q, ⁇ -carotene and carotenes.
- the phytonutrients are encapsulated by three different methods. It should be understood, however, that the disclosed preferred embodiments are merely exemplary of the invention, which may be embodied in various forms. Therefore, the details disclosed herein are not to be interpreted as limiting, but merely as the basis for the claims and for teaching one skilled in the art of the invention.
- the shell material may not be of plant origin.
- the shell material can be of polymer, sugar, gum or any combination thereof.
- Preferred shell materials include polymer of carbohydrates and phospholipids.
- Encapsulation of phytonutrients is carried out by way of dissolving the phytonutrients first in a solvent, preferably non-polar solvent.
- the non-polar solvent is hexane, heptane, chloroform or any combination thereof.
- the at least one additive is polymeric.
- Stable oil in water emulsion is achieved by dispersing the dissolved phytonutrients in an aqueous solution (i.e. buffer solution) in the presence of an emulsifier or a surface active agent.
- the solvent is then removed by distillation under vacuum or flash evaporation after which, homogenization under high pressure, i.e. more than 50bar and/or ultrasound is employed to yield emulsion of very fine particle size.
- the emulsion is dried and encapsulated phytonutrients is thus obtained.
- the encapsulated phytonutrients are tested for encapsulation efficiency and stability over time.
- the encapsulated phytonutrients are in form of nano-capsules with nano range of 20nm-500nm.
- the second method of encapsulation involves first, formation of stable oil in water emulsion.
- the steps involved in forming the stable oil in water emulsion are similar as the first method as mentioned above.
- the emulsion is then homogenized under high pressure, i.e. more than 50bar or using ultrasound.
- the homogenized emulsion is then sprayed into a solution of methanolic calcium chloride by using an atomizer.
- the solution can be of a salt solution.
- Insoluble nano-beadlets is thus formed.
- the nano-beadlets are having nano size of 20nm-500nm.
- the third method involves formation of encapsulation of the palm phytonutrients using a combination of shell materials.
- the steps involved forming the stable oil in water emulsion are similar as the first method as mentioned above.
- the shell materials consist but not confined to a sugar and gum.
- High pressure, i.e. more than 50bar or ultrasonic homogenization resulted in an emulsion of fine particle size.
- the emulsion was then dried, resulting in solid encapsulants.
- the solid encapsulants are having nano size of 20nm-500nm.
- Nano-capsules with slow release property over period of 4-6 hours are prepared by mixing or coating the beadlets or solid encapsulants with another polymeric shell material.
- the polymeric material is thus chosen from edible, food grade materials.
- the beadlets or solid encapsulants are introduced / dissolved in a shell material solution. Thereafter at least one additive is added into -the mixture obtained above and stirred.
- the beadlets or solid encapsulants are filtered from the mixture and dried.
- the beadlets or solid encapsulants are having nano size of 20nm-500nm. Releasing property of the resultant capsules were studied and recorded.
- EXAMPLE 1 1.25g mixture of tocotrienols is dissolved in 2mL dichloromethane at 50°C. To this mixture, 0.8g phospholipids, 0.15g cholesterol and 0.6g polysorbate 20 are added. The mixture is then injected into 0.01M phosphate buffer solution (pH7.4) and stirred for 30 minutes at 50°C. Excess dichloromethane is removed by distillation under vacuum. 3.2mL distilled water is then added to the mixture after removal of excess dichloromethane (tocotrienols in water dispersion) and stirred. The mixture is then subjected to homogenization using a probe ultra sonicator for 4 minutes in an ice bath. The mixture is then dried using a spray dryer. Average size of the resultant nano- capsules produced is ca. 30nm. EXAMPLE 2
- Encapsulation of mixture of carotenes is carried out in similar way as described in Example 1. 1.25g mixture of carotenes is used in place of tocotrienols. Average size of the resultant nano-capsules produced is ca. 30nm.
- 0.125g ⁇ -tocotrienol is dissolved in 0.2mL hexane at 50°C.
- 0.08g phospholipids, 0.015g cholesterol and 0.06g polysorbate 20 are added.
- the mixture is then injected into lmL 0.01M phosphate buffer solution (pH7.4) and stirred for 30 minutes at 50°C. Excess hexane is removed by distillation under vacuum. 0.3mL distilled water is then added to the mixture after removal of excess hexane ( ⁇ -tocotrienol in water dispersion) and stirred.
- the mixture is then subjected to homogenization using a probe ultra sonicator for 2 minutes in an ice bath.
- the mixture is then dried using a spray dryer. Average size of the resultant nano-capsules produced is ca. 30nm. Encapsulation efficiency is 55%.
- 0.13g a-tocotrienol is dissolved in 0.2mL chloroform at 50°C.
- 0.08g phospholipids, 0.015g cholesterol and 0.06g polysorbate 800 are added.
- the mixture is then injected into lmL 0.01M phosphate buffer solution (pH7.4) and stirred for 30 minutes at 50°C. Excess chloroform is removed by distillation under vacuum. 0.3mL distilled water is then added to the mixture after removal of excess chloroform (a- tocotrienol in water dispersion) and stirred.
- the mixture is then subjected to homogenization using a probe ultra sonicator for 2 minutes in an ice bath.
- the mixture is then dried using a spray dryer. Average size of the resultant nano-capsules produced is ca. 30nm. Encapsulation efficiency is 60%.
- Encapsulation of ⁇ -tocotrienol is carried out in similar way as in Example 5 where by ⁇ - tocotrienol is used in place of a-tocotrienol. Average size of the resultant nano-capsules produced is ca. 30nm. Encapsulation efficiency is 60%.
- Encapsulation of lycopene is carried out in similar way as in Example 5 where by lycopene is used in place of ⁇ -tocotrienol. Average size of the resultant nano-capsules produced is ca. 30nm. Encapsulation efficiency is 55%.
- EXAMPLE 8 Encapsulation of ⁇ -carotene is carried out in similar way as in Example 5 where by ⁇ - carotene is used in place of ⁇ -tocotrienol. Average size of the resultant nano-capsules produced is ca. 30nm. Encapsulation efficiency is 55%.
- EXAMPLE 9 lg mixture of tocols is dissolved in 5mL chloroform. This solution is then added into 4% aqueous sodium alginate with 2% polysorbate 80. The mixture is then subjected to sonication using a probe ultra sonicator for 3 minutes in an ice bath. The average size of tocols and sodium alginate (particles) in emulsion at this point is ca.300nm. The homogenized mixture is then added into a methanolic solution of calcium chloride with an atomizer. The resultant beadlets is then washed with methanol and dried. Encapsulation efficiency is 70%.
- Encapsulation of 0.5g coenzyme Qi 0 is carried out in similar way as described in Example 9. Average size of emulsion after ultrasonic homogenization is ca.200nm. Encapsulation efficiency is 50%.
- O. lg a -tocotrienol underwent the same process as described in Example 9. Average size of emulsion after ultrasonic homogenization is ca. 200nm. Encapsulation efficiency is 50%.
- EXAMPLE 12 O. lg ⁇ -tocotrienol underwent the same process as described in Example 9. Average size of emulsion after ultrasonic homogenization is ca. 200nm. Encapsulation efficiency is 50%.
- the tocol beadlets prepared in similar way as in Example 9 are added into a solution of 0.5% hydroxypropyl methyl cellulose in water. 40% w/w triethyl citrate purum is then added into this mixture. The mixture is then stirred for 30 minutes and coated beadlets are then filtered from the mixture, washed with water and dried. In vitro tests showed that the tocotrienols within the coated beadlets are slowly released over a period of 4 hours.
- Example 9 4g of the tocol beadlets obtained in Example 9 are added into a solution of 0.2g chitosan in water. 0.8g triethyl citrate purum and lmL acetic acid are then added into this mixture. The mixture is then stirred for 30 minutes and the coated beadlets is then filtered, washed with water and dried. In vitro tests showed that the tocotrienols within the coated beadlets are slowly released over a period of 3 hours.
- the Qio beadlets prepared in similar way as in Example 10 are added into a solution of 0.5% hydroxylpropyl methyl cellulose in water. 40% w/w triethyl citrate purum is then added into this mixture. The mixture is then stirred for 30 minutes and the coated beadlets is then filtered, washed with water and dried. In vitro tests showed that the coenzyme Qio within the coated beadlets is slowly released over a period of 4 hours.
- EXAMPLE 17 ⁇ -tocotrienol beadlets prepared in similar way as in Example 12 are treated in similar way as in Example 13. ⁇ -tocotrienol within the beadlets is slowly released over a period of 4 hours.
- EXAMPLE 18 ⁇ -tocotrienol beadlets prepared in similar way as in Example 12 are treated in similar way as in Example 14. ⁇ -tocotrienol within the beadlets is slowly released over a period of 3 hours.
- EXAMPLE 19 lg mixture of tocotrienols is dissolved in 5mL chloroform. This solution is then added into 4% aqueous sodium alginate with 2% polysorbate 80. To this mixture, hydroxypropyl methyl cellulose is added. Ratio of tocotrienols to polymer is 1:9. The mixture is stirred to dissolve for two hours. 0.8mL triethyl citrate purum is added and the mixture is stirred for another 2 hours.
- the mixture is then subjected to homogenisation using a probe ultra sonicator for 3 minutes in an ice bath.
- the average size of the particles in emulsion at this point is ca.300nm.
- the homogenized mixture is then added into a methanolic solution of calcium chloride with an atomizer.
- the resultant beadlets is then washed with methanol and dried. Encapsulation efficiency is 70%. Tocotrienols within the beadlets are slowly released over a period of 3 hours.
- arabic gum is mixed with 1.3g lactose in 9mL water. To this mixture, 0.9g mixture of tocotrienols is thus added. The mixture is then agitated before subjected to homogenization using a probe ultrasonic homogenizer for 4 minutes. Particle size of the emulsion obtained from the homogenization at this point is ca. 300nm.
- the resultant emulsion is then dried to yield dry powder. The resultant dry powder is then washed with hexane and insoluble solids are then filtered and dried. The dried solids are then added into a solution of 0.5% hydroxypropyl methyl cellulose in water. The mixture is stirred with a rotating pad at room temperature for 1 hour. Coated solids, i.e. tocotrienols nano- capsules, are then filtered from the mixture and dried.
- the encapsulation efficiency of the Arabic gum is 80% while in vitro test revealed that the tocotrienols within the nano- capsules are slowly released over 5 hours.
- Tocotrienols with slow release property using acacia gum is prepared using method similar to Example 21 with the exception that 2.0g acacia gum is used in place of Arabic gum.
- the encapsulation efficiency of the acacia gum is 80% while in vitro test revealed that the tocotrienols within the nano-capsules are slowly released over 5 hours.
- Coenzyme Qio with slow release property using arabic gum is prepared using method similar to Example 21 with the exception that 0.5g coenzyme Qio is used in place of tocotrienols.
- the encapsulation efficiency was 80% while in vitro test revealed that the coenzyme Qio within the nanocapsules is slowly released over 5 hours.
- Carotenes with slow release property using arabic gum is prepared using method similar to Example 21 with the exception that 0.5g carotenes is used in place of tocotrienols.
- the encapsulation efficiency was 80% while in vitro test revealed that the carotenes within the nano-capsules are slowly released over 5 hours.
- EXAMPLE 25 ⁇ -tocotrienol with slow release property using arabic gum is prepared using method similar to Example 21 with the exception that 0.2g ⁇ -tocotrienol is used in place of mixture of tocotrienols.
- the encapsulation efficiency was 80% while in vitro test revealed that the ⁇ -tocotrienol within the nano-capsules is slowly released over 5 hours.
- EXAMPLE 26 ⁇ - tocotrienol with slow release property using arabic gum is prepared using method similar to Example 21 with the exception that 0.2g ⁇ -tocotrienol is used in place of mixture of tocotrienols. The encapsulation efficiency was 80% while in vitro test revealed that the ⁇ -tocotrienol within the nano-capsules is slowly released over 5 hours.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a process for producing nano-capsules and beadlets containing phytonutrients derived from palm oil. The phytonutrients are such as tocotrienols, coenzyme Q and carotenes. In the present invention, the phytonutrients are encapsulated by three different processes. Sizes of the nano-capsules and nano-beadlets are in nano-range (20nm-500nm) which contributes to their stability. Shell materials are used for encapsulation of the phytonutrients. The shell materials are specially chosen to render slow property of the phytonutrients for better adsorption in vivo. Slow release of the encapsulated phytonutrients is able to ensure the phytonutrients are slowly released and remained longer in body for more efficient adsorption.
Description
A PROCESS FOR PRODUCING NANO-CAPSULES AND NANO-BEADLETS CONTAINING PHYTONUTRIENTS DERIVED FROM PALM OIL
FIELD OF INVENTION
The present invention relates to a process for producing nano-capsules and nano- beadlets containing phytonutrients derived from palm oil.
BACKGROUND OF THE INVENTION
Palm phytonutrients such as tocotrienols, carotenes and coenzyme Q are highly sensitive towards lights, temperature, pH and air. In room temperature, these phytonutrients get oxidized by air and thus, their half time is normally very short. In addition, these phytonutrients are also destroyed at extreme acidic conditions, resulting in a reduced bioavailability in vivo. In order to make up for the reduced bioavailability, larger dosage of these phytonutrients needs to be consumed thus, incurring extra cost. Therefore there is a need for encapsulation of these phytonutrients which will ensure stability, hence longer shelf life and bioavailability of the phytonutrients to reap its full benefits.
SUMMARY OF THE INVENTION
The present invention relates to a process for producing nano-capsules containing phytonutrients derived from palm oil. The, process includes the steps of:
i) dissolving the phytonutrients in a non-polar solvent;
ii) adding of at least one shell material and at least one additive into the solution obtained from step (i) to form a mixture;
iii) obtaining stable oil in water emulsion by introducing the mixture obtained from step (ii) to a buffer solution;
, iv) removing the solvent from the mixture in step (iii);
v) homogenizing the mixture obtained from step (iv) under pressure of more than 50 bar and/or by using ultrasound;
vi) drying the mixture obtained from step (v).
The phytonutrients derived from palm oil is such as tocotrienols, carotenes, coenzyme Q, γ-tocotrienol, a-tocotrienol, δ- tocotrienol, lycopene and β-carotene.
The present invention also relates to a process for producing nano-beadlets containing phytonutrients derived from palm oil. The process includes the steps of:
i) dissolving the phytonutrients in a non-polar solvent;
ii) adding of at least one shell material and at least one additive into the solution obtained from step (i) to form a mixture;
iii) homogenizing the mixture obtained from step (ii) under pressure of more than 50 bar or by way of sonication;
iv) precipitating the phytonutrients from the mixture obtained from step (iii) to form insoluble nano-beadlets; and
v) drying the insoluble nano-beadlets.
The phytonutrients is precipitated by adding the mixture obtained from step (iii) into a salt solution by using an atomizer. The salt solution is methanolic solution of calcium chloride.
The process for producing nano-beadlets containing phytonutrients derived from palm oil further includes the steps of;
i) introducing the insoluble beadlets into a shell material solution;
ii) adding at least one additive into the mixture obtained in step (i);
iii) stirring the mixture in step (ii);
iv) filtering nano-beadlets obtained from step (iii); and
v) drying the nano-beadlets.
The phytonutrients derived from palm oil is such as tocols, coenzyme Qio, tocotrienol, a- tocotrienol, γ-tocotrienol, δ-tocotrienol and carotenes. The phytonutrients within the nano-beadlets are slowly released over period of 4 - 6 hours.
The present invention also relates to a process for producing nano-capsules containing phytonutrients derived from palm oil, the process includes the steps of:
i) mixing phytonutrients with a mixture of gum and coating material in water;
ii) homogenizing the mixture obtained from step (i) under pressure of more than 50 bar or by way of sonication;
iii) drying of the emulsion obtained from step (ii);
iv) coating of insoluble solids obtained from step (iii) with shell material; and v) drying of nano-capsules obtained from step (iv).
The phytonutrients derived from palm oil is such as tocotrienol, carotenes, a-tocotrienol, and γ- tocotrienol, coenzyme Qio. The gum is such as arabic gum and acacia gum. The coating material is sugar such as lactose. The non-polar solvent used for the processes mentioned above is hexane, heptane, chloroform or any combination thereof. The shell material used for the processes mentioned above is polymer, sugar, gum or any combination thereof. The at least one additive for the processes mentioned above is polymeric. The nano-capsules or nano- beadlets obtained from the above mentioned process having size of 20nm - 500nm.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a process for producing nano-capsules and nano- beadlets containing phytonutrients derived from palm oil. The phytonutrients are such as tocols, tocotrienols, a-tocotrienols, γ-tocotrienols, δ-tocotrienol, coenzyme Q, β-carotene and carotenes. In the present invention, the phytonutrients are encapsulated by three different methods. It should be understood, however, that the disclosed preferred embodiments are merely exemplary of the invention, which may be embodied in various forms. Therefore, the details disclosed herein are not to be interpreted as limiting, but merely as the basis for the claims and for teaching one skilled in the art of the invention.
The first method called for the use of a shell material to encapsulate the phytonutrients derived from palm oil. The shell material may not be of plant origin. The shell material can be of polymer, sugar, gum or any combination thereof. Preferred shell materials include polymer of carbohydrates and phospholipids. Encapsulation of phytonutrients is carried out by way of dissolving the phytonutrients first in a solvent, preferably non-polar solvent. The non-polar solvent is hexane, heptane, chloroform or
any combination thereof. Then adding at least one shell material and at least one additive into the mixture obtained above. The at least one additive is polymeric. Stable oil in water emulsion is achieved by dispersing the dissolved phytonutrients in an aqueous solution (i.e. buffer solution) in the presence of an emulsifier or a surface active agent. The solvent is then removed by distillation under vacuum or flash evaporation after which, homogenization under high pressure, i.e. more than 50bar and/or ultrasound is employed to yield emulsion of very fine particle size. The emulsion is dried and encapsulated phytonutrients is thus obtained. The encapsulated phytonutrients are tested for encapsulation efficiency and stability over time. The encapsulated phytonutrients are in form of nano-capsules with nano range of 20nm-500nm.
The second method of encapsulation involves first, formation of stable oil in water emulsion. The steps involved in forming the stable oil in water emulsion are similar as the first method as mentioned above. The emulsion is then homogenized under high pressure, i.e. more than 50bar or using ultrasound. The homogenized emulsion is then sprayed into a solution of methanolic calcium chloride by using an atomizer. The solution can be of a salt solution. Insoluble nano-beadlets is thus formed. The nano-beadlets are having nano size of 20nm-500nm. The third method involves formation of encapsulation of the palm phytonutrients using a combination of shell materials. The steps involved forming the stable oil in water emulsion are similar as the first method as mentioned above. The shell materials consist but not confined to a sugar and gum. High pressure, i.e. more than 50bar or ultrasonic homogenization resulted in an emulsion of fine particle size. The emulsion was then dried, resulting in solid encapsulants. The solid encapsulants are having nano size of 20nm-500nm.
Nano-capsules with slow release property over period of 4-6 hours are prepared by mixing or coating the beadlets or solid encapsulants with another polymeric shell material. The polymeric material is thus chosen from edible, food grade materials. The beadlets or solid encapsulants are introduced / dissolved in a shell material solution.
Thereafter at least one additive is added into -the mixture obtained above and stirred. The beadlets or solid encapsulants are filtered from the mixture and dried. The beadlets or solid encapsulants are having nano size of 20nm-500nm. Releasing property of the resultant capsules were studied and recorded.
The invention will be further understood from the following non-limited examples. EXAMPLE 1 1.25g mixture of tocotrienols is dissolved in 2mL dichloromethane at 50°C. To this mixture, 0.8g phospholipids, 0.15g cholesterol and 0.6g polysorbate 20 are added. The mixture is then injected into 0.01M phosphate buffer solution (pH7.4) and stirred for 30 minutes at 50°C. Excess dichloromethane is removed by distillation under vacuum. 3.2mL distilled water is then added to the mixture after removal of excess dichloromethane (tocotrienols in water dispersion) and stirred. The mixture is then subjected to homogenization using a probe ultra sonicator for 4 minutes in an ice bath. The mixture is then dried using a spray dryer. Average size of the resultant nano- capsules produced is ca. 30nm. EXAMPLE 2
Encapsulation of mixture of carotenes is carried out in similar way as described in Example 1. 1.25g mixture of carotenes is used in place of tocotrienols. Average size of the resultant nano-capsules produced is ca. 30nm.
EXAMPLE 3
1.25g mixture of coenzyme Qio is dissolved in 2mL dichloromethane at 55°C. To this mixture, 0.125g phospholipids, 0.015g cholesterol and 0.06g polysorbate 20 are added. The mixture is then injected into lOmL 0.01M phosphate buffer solution (pH7.4) and agitated for 30 minutes at 50°C. Excess dichloromethane is removed by distillation under
vacuum. The mixture is then subjected to homogenization using a probe ultra sonicator for 4 minutes in an ice bath. The mixture is then dried using a spray dryer. Average size of the resultant nano-capsules produced is ca. 30nm. EXAMPLE 4
0.125g γ-tocotrienol is dissolved in 0.2mL hexane at 50°C. To this mixture, 0.08g phospholipids, 0.015g cholesterol and 0.06g polysorbate 20 are added. The mixture is then injected into lmL 0.01M phosphate buffer solution (pH7.4) and stirred for 30 minutes at 50°C. Excess hexane is removed by distillation under vacuum. 0.3mL distilled water is then added to the mixture after removal of excess hexane (γ-tocotrienol in water dispersion) and stirred. The mixture is then subjected to homogenization using a probe ultra sonicator for 2 minutes in an ice bath. The mixture is then dried using a spray dryer. Average size of the resultant nano-capsules produced is ca. 30nm. Encapsulation efficiency is 55%.
EXAMPLE 5
0.13g a-tocotrienol is dissolved in 0.2mL chloroform at 50°C. To this mixture, 0.08g phospholipids, 0.015g cholesterol and 0.06g polysorbate 800 are added. The mixture is then injected into lmL 0.01M phosphate buffer solution (pH7.4) and stirred for 30 minutes at 50°C. Excess chloroform is removed by distillation under vacuum. 0.3mL distilled water is then added to the mixture after removal of excess chloroform (a- tocotrienol in water dispersion) and stirred. The mixture is then subjected to homogenization using a probe ultra sonicator for 2 minutes in an ice bath. The mixture is then dried using a spray dryer. Average size of the resultant nano-capsules produced is ca. 30nm. Encapsulation efficiency is 60%.
EXAMPLE 6
Encapsulation of δ-tocotrienol is carried out in similar way as in Example 5 where by δ- tocotrienol is used in place of a-tocotrienol. Average size of the resultant nano-capsules produced is ca. 30nm. Encapsulation efficiency is 60%.
EXAMPLE 7
Encapsulation of lycopene is carried out in similar way as in Example 5 where by lycopene is used in place of α-tocotrienol. Average size of the resultant nano-capsules produced is ca. 30nm. Encapsulation efficiency is 55%.
EXAMPLE 8 Encapsulation of β-carotene is carried out in similar way as in Example 5 where by β- carotene is used in place of α-tocotrienol. Average size of the resultant nano-capsules produced is ca. 30nm. Encapsulation efficiency is 55%.
EXAMPLE 9 lg mixture of tocols is dissolved in 5mL chloroform. This solution is then added into 4% aqueous sodium alginate with 2% polysorbate 80. The mixture is then subjected to sonication using a probe ultra sonicator for 3 minutes in an ice bath. The average size of tocols and sodium alginate (particles) in emulsion at this point is ca.300nm. The homogenized mixture is then added into a methanolic solution of calcium chloride with an atomizer. The resultant beadlets is then washed with methanol and dried. Encapsulation efficiency is 70%.
EXAMPLE 10
Encapsulation of 0.5g coenzyme Qi0 is carried out in similar way as described in Example 9. Average size of emulsion after ultrasonic homogenization is ca.200nm. Encapsulation efficiency is 50%.
EXAMPLE 11
O. lg a -tocotrienol underwent the same process as described in Example 9. Average size of emulsion after ultrasonic homogenization is ca. 200nm. Encapsulation efficiency is 50%.
EXAMPLE 12 O. lg γ-tocotrienol underwent the same process as described in Example 9. Average size of emulsion after ultrasonic homogenization is ca. 200nm. Encapsulation efficiency is 50%.
EXAMPLE 13
The tocol beadlets prepared in similar way as in Example 9 are added into a solution of 0.5% hydroxypropyl methyl cellulose in water. 40% w/w triethyl citrate purum is then added into this mixture. The mixture is then stirred for 30 minutes and coated beadlets are then filtered from the mixture, washed with water and dried. In vitro tests showed that the tocotrienols within the coated beadlets are slowly released over a period of 4 hours.
EXAMPLE 14
4g of the tocol beadlets obtained in Example 9 are added into a solution of 0.2g chitosan in water. 0.8g triethyl citrate purum and lmL acetic acid are then added into this mixture. The mixture is then stirred for 30 minutes and the coated beadlets is then
filtered, washed with water and dried. In vitro tests showed that the tocotrienols within the coated beadlets are slowly released over a period of 3 hours.
EXAMPLE 15
The coenzyme Qio beadlets prepared in similar way as in Example 10 are treated in the same way as described in Example 14. Coenzyme Q10 within the beadlets is slowly released over a period of 3 hours. EXAMPLE 16
The Qio beadlets prepared in similar way as in Example 10 are added into a solution of 0.5% hydroxylpropyl methyl cellulose in water. 40% w/w triethyl citrate purum is then added into this mixture. The mixture is then stirred for 30 minutes and the coated beadlets is then filtered, washed with water and dried. In vitro tests showed that the coenzyme Qio within the coated beadlets is slowly released over a period of 4 hours.
EXAMPLE 17 γ-tocotrienol beadlets prepared in similar way as in Example 12 are treated in similar way as in Example 13. γ-tocotrienol within the beadlets is slowly released over a period of 4 hours.
EXAMPLE 18 γ-tocotrienol beadlets prepared in similar way as in Example 12 are treated in similar way as in Example 14. γ-tocotrienol within the beadlets is slowly released over a period of 3 hours.
EXAMPLE 19 lg mixture of tocotrienols is dissolved in 5mL chloroform. This solution is then added into 4% aqueous sodium alginate with 2% polysorbate 80. To this mixture, hydroxypropyl methyl cellulose is added. Ratio of tocotrienols to polymer is 1:9. The mixture is stirred to dissolve for two hours. 0.8mL triethyl citrate purum is added and the mixture is stirred for another 2 hours. The mixture is then subjected to homogenisation using a probe ultra sonicator for 3 minutes in an ice bath. The average size of the particles in emulsion at this point is ca.300nm. The homogenized mixture is then added into a methanolic solution of calcium chloride with an atomizer. The resultant beadlets is then washed with methanol and dried. Encapsulation efficiency is 70%. Tocotrienols within the beadlets are slowly released over a period of 3 hours.
EXAMPLE 20
1.25g mixture of tocotrienols was dissolved in 2mL dichloromethane at 50°C. To this mixture, 0.8g phospholipids, 0.15g cholesterol and 0.6g polysorbate 20 are added. The mixture is then injected into 0.01M phosphate buffer solution (pH7.4) and stirred for 30 minutes at 60°C. 3.2mL distilled water is then added to the oil in water dispersion and stirred. The mixture is then subjected to homogenisation using a probe ultra sonicator for 4 minutes in an ice bath. The mixture is then subjected to centrifugation at 3000rpm for 10 minutes. Tocotrienols nanocapsules are recovered from the supernatant. The average size of the resultant nanocapsules produced is ca. 30nm. EXAMPLE 21
2.2g arabic gum is mixed with 1.3g lactose in 9mL water. To this mixture, 0.9g mixture of tocotrienols is thus added. The mixture is then agitated before subjected to homogenization using a probe ultrasonic homogenizer for 4 minutes. Particle size of the emulsion obtained from the homogenization at this point is ca. 300nm. The resultant emulsion is then dried to yield dry powder. The resultant dry powder is then washed with
hexane and insoluble solids are then filtered and dried. The dried solids are then added into a solution of 0.5% hydroxypropyl methyl cellulose in water. The mixture is stirred with a rotating pad at room temperature for 1 hour. Coated solids, i.e. tocotrienols nano- capsules, are then filtered from the mixture and dried. The encapsulation efficiency of the Arabic gum is 80% while in vitro test revealed that the tocotrienols within the nano- capsules are slowly released over 5 hours.
EXAMPLE 22
Tocotrienols with slow release property using acacia gum is prepared using method similar to Example 21 with the exception that 2.0g acacia gum is used in place of Arabic gum. The encapsulation efficiency of the acacia gum is 80% while in vitro test revealed that the tocotrienols within the nano-capsules are slowly released over 5 hours. EXAMPLE 23
Coenzyme Qio with slow release property using arabic gum is prepared using method similar to Example 21 with the exception that 0.5g coenzyme Qio is used in place of tocotrienols. The encapsulation efficiency was 80% while in vitro test revealed that the coenzyme Qio within the nanocapsules is slowly released over 5 hours.
EXAMPLE 24
Carotenes with slow release property using arabic gum is prepared using method similar to Example 21 with the exception that 0.5g carotenes is used in place of tocotrienols. The encapsulation efficiency was 80% while in vitro test revealed that the carotenes within the nano-capsules are slowly released over 5 hours.
EXAMPLE 25 α-tocotrienol with slow release property using arabic gum is prepared using method similar to Example 21 with the exception that 0.2g α-tocotrienol is used in place of mixture of tocotrienols. The encapsulation efficiency was 80% while in vitro test revealed that the α-tocotrienol within the nano-capsules is slowly released over 5 hours.
EXAMPLE 26 γ- tocotrienol with slow release property using arabic gum is prepared using method similar to Example 21 with the exception that 0.2g α-tocotrienol is used in place of mixture of tocotrienols. The encapsulation efficiency was 80% while in vitro test revealed that the γ-tocotrienol within the nano-capsules is slowly released over 5 hours.
Claims
1. A process for producing nano-capsules containing phytonutrients derived from palm oil, the process includes the steps of:
i) dissolving the phytonutrients in a non-polar solvent;
ii) adding of at least one shell material and at least one additive into the solution obtained from step (i) to form a mixture;
iii) obtaining stable oil in water emulsion by introducing the mixture obtained from step (ii) to a buffer solution;
iv) removing the solvent from the mixture in step (iii);
v) homogenizing the mixture obtained from step (iv) under pressure of more than 50 bar and/or by using ultrasound;
vi) drying the mixture obtained from step (v).
2. The process for producing nano-capsules containing phytonutrients oil derived from palm oil as claimed in claim 1 wherein the phytonutrients is such as tocotrienols, carotenes, coenzyme Q, γ-tocotrienol, a-tocotrienol, δ- tocotrienol, lycopene and β-carotene.
3. The process for producing nano-capsules containing phytonutrients derived from palm oil as claimed in claim 1 wherein the nano-capsules having size of 20nm - 500nm.
4. The process for producing nano-capsules containing phytonutrients derived from palm oil as claimed in claim 1 wherein the non-polar solvent is hexane, heptane, chloroform or any combination thereof.
5. The process for producing nano-capsules containing phytonutrients derived from palm oil as claimed in claim 1 wherein the at least one shell material is polymer, sugar, gum or any combination thereof.
6. The process for producing nano-capsules containing phytonutrients derived from palm oil as claimed in claim 1 wherein the at least one additive is polymeric.
7. The process for producing nano-capsules containing phytonutrients derived from oil as claimed in claim 1 wherein the nano-capsules having size of 20nm - 500nm.
8. A process for producing nano-beadlets containing phytonutrients derived from palm oil, the process includes the steps of:
i) dissolving the phytonutrients in a non-polar solvent;
ii) adding of at least one shell material and at least one additive into the solution obtained from step (i) to form a mixture;
iii) homogenizing the mixture obtained from step (ii) under pressure of more than 50 bar or by way of sonication;
iv) precipitating the phytonutrients from the mixture obtained from step (iii) to form insoluble nano-beadlets; and
v) drying the insoluble nano-beadlets.
9. The process for producing nano-beadlets containing phytonutrients derived from palm oil as claimed in claim 8 wherein the phytonutrients is -such as tocols, coenzyme Qio, tocotrienol, a-tocotrienol, γ-tocotrienol, δ-tocotrienol and carotenes.
10. The process for producing nano-beadlets containing phytonutrients derived from palm oil as claimed in claim 8 wherein the phytonutrients is precipitated by adding the mixture obtained from step (iii) into a salt solution by using an atomizer.
11. The process for producing nano-beadlets containing phytonutrients derived from palm oil as claimed in claim 10 wherein the salt solution is methanolic solution of calcium chloride.
12. The process for producing nano-beadlets containing phytonutrients derived from palm oil as claimed claim 8 wherein the process further includes the steps of: i) introducing the insoluble beadlets into a shell material solution;
ii) adding at least one additive into the mixture obtained in step (i);
iii) stirring the mixture in step (ii);
iv) filtering nano-beadlets obtained from step (iii); and
v) drying the nano-beadlets.
13. The process for producing nano-beadlets containing phytonutrients derived from oil as claimed in claim 8 wherein the nano-beadlets having size of 20nm - 500nm.
14. The process for producing nano-beadlets containing phytonutrients derived from palm oil as claimed in claim 8 wherein the non-polar solvent is hexane, heptane, chloroform or any combination thereof.
15. The process for producing nano-beadlets containing phytonutrients derived from palm oil as claimed in claims 8 and 12 wherein the shell material is polymer, sugar, gum or any combination thereof.
16. The process for producing nano-beadlets containing phytonutrients derived from palm oil as claimed in claims 8 and 12 wherein the at least one additive is polymeric.
17. The process for producing nano-beadlets containing phytonutrients derived from palm oil as claimed in claim 8 wherein the phytonutrients within the nano- beadlets are slowly released over period of 4 - 6 hours.
18. A process for producing nano-capsules containing phytonutrients derived from palm oil, the process includes the steps of:
i) mixing phytonutrients with a mixture of gum and coating material in water; ii) homogenizing the mixture obtained from step (i) under pressure of more than 50 bar or by way of sonication; iii) drying of the emulsion obtained from step (ii);
iv) coating of insoluble solids obtained from step (iii) with shell material; and v) drying of nano-capsules obtained from step (iv).
19. The process for producing nano-capsules containing phytonutrients derived from palm oil as claimed in claim 18 wherein the phytonutrients is such as tocotrienol, carotenes, a-tocotrienol, and γ-tocotrienol , coenzyme Qio.
20. The process for producing nano-capsules containing phytonutrients derived from palm oil as claimed in claim 18 wherein the gum is arabic gum.
21. The process for producing nano-capsules containing phytonutrients derived from palm oil as claimed in claim 18 wherein the gum is acacia gum.
22. The process for producing nano-capsules containing phytonutrients derived from palm oil as claimed in claim 18 wherein the coating material is sugar such as lactose.
23. The process for producing nano-capsules containing phytonutrients derived from palm oil is claimed in claim 18 wherein the shell material is polymer.
24. The process for producing nano-capsules containing phytonutrients derived from palm oil is claimed in claim 18 wherein the nano-capsules having size of 20nm - 500nm.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG2013085253A SG195029A1 (en) | 2011-05-23 | 2012-05-23 | A process for producing nano-capsules and nano-beadlets containing phytonutrients derived from palm oil |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MYPI2011002294A MY159478A (en) | 2011-05-23 | 2011-05-23 | A process for producing nano-capsules and nano-beadlets containing phytonutrients derived from palm oil |
MYPI2011002294 | 2011-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012161562A1 true WO2012161562A1 (en) | 2012-11-29 |
Family
ID=47217465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MY2012/000106 WO2012161562A1 (en) | 2011-05-23 | 2012-05-23 | A process for producing nano-capsules and nano-beadlets containing phytonutrients derived from palm oil |
Country Status (3)
Country | Link |
---|---|
MY (1) | MY159478A (en) |
SG (1) | SG195029A1 (en) |
WO (1) | WO2012161562A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10973763B2 (en) | 2011-06-17 | 2021-04-13 | Berg Llc | Inhalable pharmaceutical compositions |
US11400058B2 (en) | 2010-03-12 | 2022-08-02 | Berg Llc | Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040037903A1 (en) * | 2001-06-13 | 2004-02-26 | Lemmo Edward A. | Phytonutrient formula for the relief of chronic pain resulting from inflammation |
US20060003947A1 (en) * | 2005-06-03 | 2006-01-05 | Udell Ronald G | Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols |
US7119238B2 (en) * | 2000-07-12 | 2006-10-10 | University Of Maryland | Process for purification and crystallization of palm oil carotenoids |
US7575767B2 (en) * | 2002-08-20 | 2009-08-18 | Malaysian Palm Oil Board | Extraction of palm vitamin E, phytosterols and squalene from palm oil |
US20090324705A1 (en) * | 2008-02-13 | 2009-12-31 | Nina Vikhrieva | Phytonutrient compositions for topical use |
-
2011
- 2011-05-23 MY MYPI2011002294A patent/MY159478A/en unknown
-
2012
- 2012-05-23 WO PCT/MY2012/000106 patent/WO2012161562A1/en active Application Filing
- 2012-05-23 SG SG2013085253A patent/SG195029A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7119238B2 (en) * | 2000-07-12 | 2006-10-10 | University Of Maryland | Process for purification and crystallization of palm oil carotenoids |
US20040037903A1 (en) * | 2001-06-13 | 2004-02-26 | Lemmo Edward A. | Phytonutrient formula for the relief of chronic pain resulting from inflammation |
US7575767B2 (en) * | 2002-08-20 | 2009-08-18 | Malaysian Palm Oil Board | Extraction of palm vitamin E, phytosterols and squalene from palm oil |
US20060003947A1 (en) * | 2005-06-03 | 2006-01-05 | Udell Ronald G | Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols |
US20090324705A1 (en) * | 2008-02-13 | 2009-12-31 | Nina Vikhrieva | Phytonutrient compositions for topical use |
Non-Patent Citations (1)
Title |
---|
C. E. MORA-HUERTAS ET AL.: "Polymer-based nanocapsules for drug delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 385, 2010, pages 113 - 142 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11400058B2 (en) | 2010-03-12 | 2022-08-02 | Berg Llc | Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof |
US10973763B2 (en) | 2011-06-17 | 2021-04-13 | Berg Llc | Inhalable pharmaceutical compositions |
Also Published As
Publication number | Publication date |
---|---|
MY159478A (en) | 2017-01-13 |
SG195029A1 (en) | 2013-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mahalakshmi et al. | Micro-and nano-encapsulation of β-carotene in zein protein: Size-dependent release and absorption behavior | |
Gómez-Mascaraque et al. | Coaxial electrospraying of biopolymers as a strategy to improve protection of bioactive food ingredients | |
Carpentier et al. | Microencapsulation and controlled release of α-tocopherol by complex coacervation between pea protein and tragacanth gum: A comparative study with arabic and tara gums | |
RU2598748C1 (en) | Method of producing nanocapsules of adaptogens in sodium alginate | |
RU2590693C1 (en) | Method of producing nano capsules of adaptogens in pectin | |
RU2606854C1 (en) | Method of producing nanocapsules of dry spinach extract | |
WO2012161562A1 (en) | A process for producing nano-capsules and nano-beadlets containing phytonutrients derived from palm oil | |
RU2569736C1 (en) | Method of production of nanocapsules of adenine in sodium alginate | |
RU2555824C1 (en) | Method for production of microcapsules of dry girasol extract in pectin | |
KR101849928B1 (en) | Method for preparing nano-micro starch gel particles by using W/O emulsion | |
RU2631883C2 (en) | Method for production of nanocapules of penicillin group medicine preparations in konjac gum | |
RU2640130C2 (en) | Method for producing nanocapsules of dry extract of topinambur | |
RU2552325C2 (en) | Method for producing antioxidant microcapsules | |
RU2611367C1 (en) | Method of producing of microcapsules of tetracycline antibiotics in sodium alginatemethod of producing of microcapsules of aminoglycoside antibiotics in sodium alginate | |
RU2605614C1 (en) | Method of producing nanocapsules of dry girasol extract | |
RU2627581C2 (en) | Method of producing nanocapules of chloralhydrate in kappa-carraginane | |
RU2599007C1 (en) | Method of producing nanocapsules of ciprofloxacin hydrochloride in sodium alginate | |
RU2569734C2 (en) | Method of producing nanocapsules of resveratrol in sodium alginate | |
RU2654229C1 (en) | Method for producing nanocapsules of vitamins in pectin | |
RU2640127C2 (en) | Method for producing nanocapsules of dry extract of topinambur | |
RU2590651C1 (en) | Method of riboflavin nano capsules producing in gellan gum | |
RU2632428C1 (en) | Method for obtaining of girasole dry extract nanocapules in xanthane gum | |
RU2622752C1 (en) | Method for spinage dry extract nanocapules production | |
RU2634256C2 (en) | Method for producing nanocapules of dry extract of topinambur | |
RU2627580C2 (en) | Method of obtaining nanocapules of antibiotics of tetracyclin row in konjac gum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12790242 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12790242 Country of ref document: EP Kind code of ref document: A1 |